VIDEO: President discusses the approval of Avastin in France

PARIS — At the meeting of the French Society of Ophthalmology, Jean Françoise Korobelnik, MD, President of the SFO, talks about the recent provisions of the French government in favor of Avastin, which will be allowed in public hospitals to treat patients with wet AMD. Issues remain concerning safe compounding, costs and criteria for assigning patients to be treated with Avastin, Lucentis or Eylea. A second government provision is the approval and funding of Argus II, which will be implanted in 36 selected patients.

FibroGen Announces First Quarter 2015 Financial Results

SAN FRANCISCO–(BUSINESS WIRE)–FibroGen, Inc. (NASDAQ:FGEN) (“FibroGen”), a research-based biopharmaceutical company, today reported financial results for the quarter ended March 31, 2015. “FibroGen and its partners, AstraZeneca and Astellas, continue to make excellent progress in the global development of roxadustat for the treatment of anemia in patients with chronic kidney disease,” said Thomas B. Neff, chief executive officer of FibroGen. “Patient enrollment in the seven Phase 3 studies re